<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168803</url>
  </required_header>
  <id_info>
    <org_study_id>15340</org_study_id>
    <secondary_id>I1V-MC-EIBM</secondary_id>
    <nct_id>NCT02168803</nct_id>
  </id_info>
  <brief_title>A Study of Evacetrapib in Participants With Abnormal Cholesterol</brief_title>
  <official_title>A Phase 1b Study to Characterize the Pharmacokinetics of Evacetrapib and Potential for Accumulation After Dosing for 12, 24, and 52 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to measure how much of the drug gets into the blood stream
      and how long it takes the body to get rid of it when given once a day for 12, 24, and 52
      weeks to participants with abnormal amounts of cholesterol and/or fat in the blood stream.
      Information about any side effects that may occur will also be collected.

      This study will also evaluate how the study drug reacts in the body when given once a day for
      12, 24 and 52 weeks and how the body responds and returns to normal when the treatment is
      complete. The relationship between study drug and the results from the how the study drug
      reacts in the body may be explored, if needed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameters of Evacetrapib: Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Last dose up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) Parameters of Evacetrapib: Maximum Concentration (Cmax)</measure>
    <time_frame>Last dose up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameters of Evacetrapib: Terminal Half-life</measure>
    <time_frame>Last dose up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Parameters of Evacetrapib: High Density Lipoprotein Cholesterol (HDL-C) Level</measure>
    <time_frame>Last dose up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Parameters of Evacetrapib: Low-Density Lipoprotein Cholesterol (LDL-C) Level</measure>
    <time_frame>Last dose up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Parameters of Evacetrapib: Total Cholesterol Level</measure>
    <time_frame>Last dose up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Parameters of Evacetrapib: Triglyceride Level</measure>
    <time_frame>Last dose up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Evacetrapib: Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of evacetrapib on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib: Multiple Dose 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib: Multiple Dose 24 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib: Multiple Dose 52 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Evacetrapib: Single Dose</arm_group_label>
    <arm_group_label>Evacetrapib: Multiple Dose 12 Weeks</arm_group_label>
    <arm_group_label>Evacetrapib: Multiple Dose 24 Weeks</arm_group_label>
    <arm_group_label>Evacetrapib: Multiple Dose 52 Weeks</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy participants or have stable medical conditions that, in the
             investigator's opinion, will not significantly alter the disposition of the drug, will
             not place the participant at increased risk by participating in the study, and will
             not interfere with interpretation of the data and meets one of the following criteria:

               -  Elevated low-density lipoprotein cholesterol (LDL-C) greater than 100 milligrams
                  per deciliter (mg/dL), OR

               -  Low high-density lipoprotein cholesterol (HDL-C) less than 45 mg/dL (men); less
                  than 50 mg/dL (women), OR

               -  Hypercholesterolemia on stable statin therapy for at least 3 month

          -  Have a body mass index (BMI) of 18 to 37 kilograms per square meter (kg/m^2),
             inclusive, at screening

        Exclusion Criteria:

          -  Have known allergies or intolerance to evacetrapib, related compounds

          -  Have history of recurrent rashes or chronic skin conditions

          -  Have significant history of or current chronic, active inflammatory conditions

          -  Have history or current evidence of significant neurological disorder

          -  Have long-standing diabetes that is insulin requiring

          -  Have history of or current symptoms of malabsorption syndromes, history of gastric
             bypass surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abnormal cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

